Tribune News Service
New Delhi, September 15
The ICMR stated on Tuesday early proof from one in all its randomised managed trials on the efficacy of convalescent plasma has proven that the remedy didn’t cut back mortality nor did it forestall development from average to extreme illness.
ICMR chief Balram Bhargava stated the research carried out on 464 sufferers throughout 39 hospitals was nonetheless below peer evaluation and full publication of the outcomes was awaited.
“Once we get the final publication we will take a decision on whether to continue advising use of plasma therapy as an off label therapy for COVID management in India,” Bhargava stated indicating potentialities of evaluation of the earlier steerage by ICMR and consequent nervousness amongst a number of COVID sufferers to safe convalescent plasma.
Several states have gone to the extent of establishing plasma banks with the efficacy of the remedy nonetheless unproven.